CCRM Australia accelerates the commercialisation of Australian regenerative medicine therapies and related technologies. We do this through engagement and fostering local and international collaboration between industry, clinicians and academia; thereby nurturing local regenerative medicine companies for the international market.
National Regenerative Medicine SuperPitch
The Centre for Commercialization of Regenerative Medicine (CCRM) Australia has partnered with local and international venture capital firms to launch the National Regenerative Medicine SuperPitch. The SuperPitch offers expertise and investment funding for translation and commercialisation of Australian projects related to regenerative medicine.
Regenerative medicine includes technologies and therapies that regenerate or replace injured, diseased, or defective cells, tissues, or organs to restore or establish function and structure. Submissions may relate to cell therapies, gene therapies, combination therapies, gene editing tools, enabling technologies such as vector production, automated analytical assays, biosensors, novel media, and other projects related to regenerative medicine in a wide range of therapeutic area.
The National Regenerative Medicine SuperPitch provides an opportunity for companies and researchers to showcase their technologies or ideas. Expert feedback, commercialisation support from CCRM Australia and, for suitable projects, further development funding will be made available. The participation of partners with expertise in various specialties and lifecycle stages empowers the SuperPitch to streamline progress from proof of concept through to clinical trials.
Shortlisted applicants will be invited to provide a forty-minute presentation, which must include objective data on their technologies to a panel of regenerative medicine, venture capital and commercialisation experts from the consortia.
The inaugural National Regenerative Medicine SuperPitch will be held on the 24th of July 2020. If the ongoing COVID-19 pandemic allows, the event will be held at the Monash Conference Centre, 30 Collins St, Melbourne. Either way, video conference facilities will be made available for all participants.
- Application via expression of interest close 5 pm AEST 5th June 2020
- Shortlisted applicants will be informed during the week commencing 29th June 2020
- SuperPitch event: 24th July
Contact: Dr Jack Lambshead, email@example.com.
CCRM Australia 2019 Annual Report
CCRM Australia Prospectus
CCRM Australia 2018 Annual Report
The last 12 months have seen significant progress with CCRM Australia. With the endorsement of the 5-year strategic plan by the CCRM Australia Council and its subsequent approval by key stakeholders, CCRM Australia have been able to address many critical operational objectives and achieved several key milestones.
What is CCRM?
Australia’s leading regenerative medicine researchers have come together in a coordinated, collaborative fashion to support the creation of CCRM Australia.
CCRM Australia is a not for profit established to address bottlenecks in the translation and commercialisation of RM discoveries in Australia.
CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate to CCRM.
As a member of the Global CCRM network, CCRM Australia is a partner to a leading edge industry consortium. CCRM Australia is taking RM from bench to bedside by treating and potentially curing some of the most devastating and costly diseases in the world today.
What is Canada’s Centre for Commercialization of Regenerative Medicine (CCRM)?
Since its inception in 2011, CCRM has become globally recognised as a translation centre and has become a leading global commercial hub for regenerative medicine and cell therapy. In partnership with top research institutions in Canada and abroad, and with a consortium of global industry leaders, CCRM has established a track record of developing and commercialising innovative technologies that tackle significant bottlenecks in the industry.
Examples of this include:
- evaluation of novel biomaterials to enable cell product shipping,
- process optimisation on a cell therapy resulting in a 60% reduction in cost of goods,
- advancement of two novel drug screening platforms aimed at the direct measurement of contraction forces by contractile cells,
- co-development of image analysis software to enable analysis in a novel drug screening platform,
- development of novel cryopreservation approaches for specialised cells, and
- development of scalable expansion protocols for pluripotent stem cells.
CCRM has developed and implemented an efficient model for technology transfer that includes:
- in-licensing of technologies,
- value adding development either alone or in partnership with companies or academics,
- out-licensing of technologies/ processes to existing companies, and
- the bundling of technologies to create spin-out companies.
CCRM has approached ARMI at the Monash University Clayton Campus to establish an Australian ‘hub’ modelled along the CCRM operational model. This hub will be developed in parallel with other emerging hubs in Israel, Japan, Europe and Singapore.
The benefits of the introduction of the CCRM model to Australia include:
- immediate access to a demonstrated commercialisation model and sector specific expertise developed by CCRM to be utilised for the benefit of local regenerative medicine discoveries
- regenerative medicine product development, licensing and regulatory expertise
- membership of a large consortium that includes the major companies working in regenerative medicine
- access to a consortium of world-leading regenerative medicine companies providing business skills and leadership, funds for product development, and receptor capacity for technologies and products
- strong link to industry trends and needs through the industry consortium